The National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, awarded a single-award Indefinite Delivery Contract (IDC) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., with a potential value of $6.6 billion over 5 years. This establishes Leidos Biomedical Research Inc. as a Federally Funded Research and Development Center (FFRDC) to provide a broad range of biomedical research and facilities support services to the NCI and other NIH institutes.
Under this IDC, the NCI has awarded multiple task orders to Leidos Biomedical Research Inc. for services such as operational support, facilities improvements, clinical and translational data management, vaccine development, proteomic analysis, and specialized laboratory testing and manufacturing. The work is primarily performed at Leidos facilities in Fort Detrick and Frederick, Maryland. These task orders do not utilize any small business set-asides, as Leidos Biomedical Research Inc. is leveraging its FFRDC status and expertise to support the NCI's and NIAID's biomedical research priorities across disease areas including cancer, infectious diseases, and gene therapy.
Generated 1/23/25, 9:06 AM